{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-803+alone",
    "query": {
      "intervention": "N-803 alone"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-803+alone&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T07:37:46.953Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04491955",
      "title": "Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Bowel Cancers",
        "Colorectal Cancers"
      ],
      "interventions": [
        {
          "name": "CV301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MSB0011359C",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "NHS-IL12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-09-22",
      "completion_date": "2024-08-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04491955"
    },
    {
      "nct_id": "NCT07123727",
      "title": "A Study to Examine Anktiva for the Treatment of COVID-19.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long COVID Syndrome",
        "Long Covid 19"
      ],
      "interventions": [
        {
          "name": "Anktiva",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-04",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07123727"
    },
    {
      "nct_id": "NCT05245292",
      "title": "3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS",
          "type": "DRUG"
        },
        {
          "name": "10-1074-LS",
          "type": "DRUG"
        },
        {
          "name": "N803",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2022-12-07",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 3,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05245292"
    },
    {
      "nct_id": "NCT06061809",
      "title": "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields (TTFields, 200 kHz)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2024-08-07",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 4,
      "location_summary": "El Segundo, California • Fullerton, California • Newport Beach, California + 1 more",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06061809"
    },
    {
      "nct_id": "NCT03520686",
      "title": "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NAI + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Nivolumab + Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Nab-paclitaxel + Atezolizumab + NAI",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin and Nab-paclitaxel plus Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2018-05-18",
      "completion_date": "2025-10-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 31,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520686"
    },
    {
      "nct_id": "NCT05445882",
      "title": "N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Bintrafusp alfa",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "BN-Brachyury",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2024-04-01",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05445882"
    },
    {
      "nct_id": "NCT04247282",
      "title": "Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "M7824",
          "type": "DRUG"
        },
        {
          "name": "N803",
          "type": "DRUG"
        },
        {
          "name": "TriAd vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-06-09",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2025-07-16",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04247282"
    },
    {
      "nct_id": "NCT05618925",
      "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin's Lymphoma Refractory/Relapsed"
      ],
      "interventions": [
        {
          "name": "N803",
          "type": "DRUG"
        },
        {
          "name": "CD19t-haNK suspension",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-22",
      "completion_date": "2027-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Tyler, Texas",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05618925"
    },
    {
      "nct_id": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Microsatellite Instability",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "N-803 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Pembrolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-12-11",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03228667"
    },
    {
      "nct_id": "NCT06710288",
      "title": "A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-CENK",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 85 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2024-11-06",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-03T07:37:46.953Z",
      "location_count": 2,
      "location_summary": "El Segundo, California • Newport Beach, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06710288"
    }
  ]
}